Bank of India Large & Mid Cap Fund
The scheme aims at income and long-term capital appreciation by investing through a diversified portfolio of predominantly large cap and mid cap equity and equity-related securities including equity derivatives.
Growthvine rating: 2/5 — ranked #28 of 41 in category.
Fund basics
| Category | Equity: Large & Mid Cap |
|---|
| NAV | ₹88.22 (as of 2026-10-01) |
|---|
| AUM | ₹529 Cr |
|---|
| Expense ratio | 2.09% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nitin Gosar |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 3 months |
|---|
Performance & risk
| 5-year annualised return | 9.87% |
|---|
| Sharpe ratio | 0.56 |
|---|
| Standard deviation | 15.74% |
|---|
| Max drawdown | −39.51% |
|---|
| Alpha | 2.25 |
|---|
| Beta | 1.01 |
|---|
Over 5 years, captured 95.5% of NIFTY LargeMidcap 250's upside and 99.7% of its downside.
Market cap allocation
| Large cap | 42.8% |
|---|
| Mid cap | 41.1% |
|---|
| Small cap | 16.1% |
|---|
Concentration
| Top 5 holdings | 26.1% |
|---|
| Top 10 holdings | 42.7% |
|---|
| Total holdings | 50 |
|---|
| Index overlap | 25.9% |
|---|
| Active share | 74.1% |
|---|
Top holdings
- HDFC Bank Ltd. — 7.5%
- Reliance Industries Ltd — 6.3%
- Dixon Technologies (India) Limited — 4.4%
- FSN E-Commerce Ventures Limited — 4.3%
- Kotak Mahindra Bank Ltd. — 3.7%
- Aurobindo Pharma Ltd. — 3.6%
- Larsen & Toubro Limited — 3.5%
- State Bank Of India — 3.3%
- PB Fintech Limited — 3.2%
- TREPS — 3.2%
Top sectors
- Banking & Financial — 18.2%
- Pharma & Biotech — 11.8%
- Retail — 8.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −4.1% | Q2 | #16 of 38 |
| 2025 | 6.8% | Q2 | #12 of 34 |
| 2024 | 16.6% | Q4 (Bottom) | #23 of 29 |
| 2023 | 29.3% | Q3 | #16 of 28 |
| 2022 | 1.9% | Q2 | #14 of 28 |